Clinical Trials Browser

Neuroblastoma, Dysbiosis

NCT05064306 2025-08-01

131I-omburtamab for the Treatment of Central Nervous System/Leptomeningeal Neoplasms in Children and Young Adults

CNSGastrointestinalGenitourinaryOther solid neoplasmSarcoma

Medulloblastoma, Meningeal Neoplasms, Wilms Tumor, Neuroblastoma, Pinealoma, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Rhabdoid Tumor

Clinical Trials

Fecal Microbiota Transplant for Neuroblastoma in a Single Patient

131I-omburtamab for the Treatment of Central Nervous System/Leptomeningeal Neoplasms in Children and Young Adults

131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed/Refractory Neuroblastoma

Expanded Access to OKN-007 for Patients With Diffuse Midline Glioma, H3 K27-altered

Expanded Access Program for Avapritinib

TVI-Brain-1 in Expanded Access Patient

Treatment of Recurrent GBM With APG-157 Via Expanded Access

TRIANGLE

Expanded Access for KHK2455

Expanded Access Protocol Using 131I-MIBG Therapy +/- Vorinostat for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma

EAP for the Treatment of Glioblastoma With PVSRIPO

Expanded Access Study of Fenretinide Lym-X-Sorb Plus Ketoconazole in Neuroblastoma

Individual Patient Compassionate Use of GX-I7

Expanded Access Use of Tucatinib for HER2+ Metastatic Breast Cancer

Compassionate Use Arm - ABI541 ABI for 10 NF2 Patients

An Expanded Access Program of Ipilimumab for Patients With Glioblastomas and Gliomas

Expanded Access for Pembrolizumab (MK-3475)

CDX-110

Expanded Access to ANG1005 for Individual Patients